Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Takeda Pharmaceutical Ltd ADR (TAK)

Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
One Ultra-Cheap High-Yield Dividend Stock to Buy

Now may be a good time for dividend investors to consider loading up on this stock.

TAK : 13.02 (-0.31%)
Orphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That Time

There are very good reasons that stocks generally gain in value after a company receives %OrphanDrug designation (ODD). A study published in Orphanet Journal of Rare Diseases showed that the average stock...

SNY : 49.00 (-2.70%)
TAK : 13.02 (-0.31%)
NRX.VN : 0.480 (unch)
BMY : 41.54 (-1.89%)
NRX : 0.14 (+7.69%)
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. Positive Opinion...

TAK : 13.02 (-0.31%)
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris

One of these high-yield pharma stocks stands out as a better buy right now.

PFE : 28.69 (-3.07%)
TAK : 13.02 (-0.31%)
VTRS : 10.53 (-3.17%)
2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now

These two high-yield dividend stocks are attractive buys right now.

TAK : 13.02 (-0.31%)
T : 17.47 (-0.17%)
Why Shares of Innate Pharma Jumped Thursday

The company's collaboration agreement with Sanofi could soon pay off.

SNY : 49.00 (-2.70%)
TAK : 13.02 (-0.31%)
IPHA : 2.96 (-1.33%)
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) resubmission for the investigational...

TAK : 13.02 (-0.31%)
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday

The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.

AMGN : 306.50 (-0.94%)
GSK : 45.15 (-1.38%)
TAK : 13.02 (-0.31%)
ARWR : 24.67 (-1.87%)
This Supercharged Dividend King Stock Might Soon Run Out of Steam

Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.

JNJ : 149.70 (-2.48%)
PFE : 28.69 (-3.07%)
BMY : 41.54 (-1.89%)
TAK : 13.02 (-0.31%)
GILD : 66.17 (-2.40%)
VRTX : 450.80 (+0.73%)
ABBV : 158.26 (-0.85%)
ABT : 104.23 (-0.56%)
MRK : 131.09 (-0.01%)
RXDX : 199.92 (+0.09%)
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children

Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) to expand the use of HYQVIA to treat primary...

TAK : 13.02 (-0.31%)

Barchart Exclusives

Stock Index Futures Rebound from Thursday’s Sell-Off, U.S. Economic Data on Tap
June S&P 500 E-Mini futures (ESM24) are up +0.23%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.22% this morning, rebounding slightly from yesterday’s slump prompted by strong U.S. economic data, which heightened speculation that the Federal Reserve might keep rates on hold for most of this year. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar